Zymeworks Inc.: Zymeworks Outlines Strategic Priorities and Outlook for 2026

Positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone ...

What Investors Should Know About a $511K Disc Medicine Insider Sale and a 26% Stock Run

This clinical-stage biotech specializing in blood disorders reported a notable insider sale amid strong recent stock ...

Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva’s anti-IL-15 candidate, TEV-‘408 ...

Zymeworks Outlines Strategic Priorities and Outlook for 2026

GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GIUp to $440.0 million in milestone payments eligible to be e ...

AqueLyst Introduces Duo Equine Horse Stall Odor Eliminator for Barn and Stable Environments

WILMINGTON, DE, UNITED STATES, January 9, 2026 /EINPresswire.com/ -- AqueLyst, a provider of environmental and ...